Posted On: 07/24/2014 8:23:58 AM
Post# of 30066
Gerald seems confident about MANF's chances against competing NF rhNGF.
By the way, this was from Sept 2013
Dompé announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for retinitis pigmentosa
Retinitis pigmentosa includes a group of hereditary eye diseases with progressive loss of vision for which currently there is no cure
Retinitis pigmentosa affects about 3 in 10,000 people in the US
Dompé, which recently opened a subsidiary in the US, is one of the leading biopharmaceutical company in Italy and a global player in the development of innovative treatment solutions for rare orphan diseases in ophthalmology
Milan, September 11th, 2013 – Dompé, the leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) discovered by Nobel Laureate Professor Rita Levi Montalcini has been granted orphan drug designation by the US FDA for the treatment of retinitis pigmentosa (RP). This gives new hope for the treatment of this disease for which at present there is no cure.
By the way, this was from Sept 2013
Dompé announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for retinitis pigmentosa
Retinitis pigmentosa includes a group of hereditary eye diseases with progressive loss of vision for which currently there is no cure
Retinitis pigmentosa affects about 3 in 10,000 people in the US
Dompé, which recently opened a subsidiary in the US, is one of the leading biopharmaceutical company in Italy and a global player in the development of innovative treatment solutions for rare orphan diseases in ophthalmology
Milan, September 11th, 2013 – Dompé, the leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) discovered by Nobel Laureate Professor Rita Levi Montalcini has been granted orphan drug designation by the US FDA for the treatment of retinitis pigmentosa (RP). This gives new hope for the treatment of this disease for which at present there is no cure.
(0)
(0)
